Home Cart Sign in  
Chemical Structure| 864750-70-9 Chemical Structure| 864750-70-9

Structure of Revefenacin
CAS No.: 864750-70-9

Chemical Structure| 864750-70-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TD-4208 is a long-actingmuscarinic cholinergic receptor (mAChR) antagonist and may be potentially useful for the treatment of respiratory disease.

Synonyms: TD-4208; GSK1160724

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Revefenacin

CAS No. :864750-70-9
Formula : C35H43N5O4
M.W : 597.75
SMILES Code : O=C(OC1CCN(CCN(C(C2=CC=C(CN3CCC(C(N)=O)CC3)C=C2)=O)C)CC1)NC4=CC=CC=C4C5=CC=CC=C5
Synonyms :
TD-4208; GSK1160724
MDL No. :MFCD28386316
InChI Key :FYDWDCIFZSGNBU-UHFFFAOYSA-N
Pubchem ID :11753673

Safety of Revefenacin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03095456 Chronic Obstructive Pulmonary ... More >>Disease, COPD Low Peak Inspiratory Flow Rate (PIFR) Less << Phase 3 Completed - United States, South Carolina ... More >> Clinical Research of Rock Hill Rock Hill, South Carolina, United States, 29732 Less <<
NCT03573817 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << Phase 3 Completed - United States, Oregon ... More >> Theravance Biopharma Call Center Medford, Oregon, United States, 97504 Less <<
NCT01704404 - Completed - -
NCT02040792 COPD Phase 2 Completed - United States, South Carolina ... More >> Upstate Pharmaceutical Research Greenville, South Carolina, United States, 29615 Less <<
NCT02820311 Cardiac Repolarization in Heal... More >>thy Subjects Less << Phase 1 Completed - United States, Arizona ... More >> Celerion Tempe, Arizona, United States, 85283 Less <<
NCT02459080 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << Phase 3 Completed - United States, Oregon ... More >> Allergy Associates Research Center (AARC) Portland, Oregon, United States, 97202 Less <<
NCT01704404 COPD Phase 2 Completed - New Zealand ... More >> P3 Research Ltd Wellington, New Zealand Less <<
NCT02512510 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << Phase 3 Completed - United States, South Carolina ... More >> Palmetto Medical Research Associates L.L.C. Easley, South Carolina, United States, 29640 Less <<
NCT02518139 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << Phase 3 Completed - United States, South Carolina ... More >> Palmetto Medical Research Associates L.L.C Easley, South Carolina, United States, 29640 Less <<
NCT03064113 Chronic Obstructive Pulmonary ... More >>Disease, COPD Less << Phase 2 Completed - New Zealand ... More >> P3 Research Wellington, New Zealand, 6021 Less <<
NCT02040792 - Completed - -
NCT02772159 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << PHASE1 COMPLETED 2025-04-16 Celerion, Lincoln, Nebraska, 6... More >>8502, United States Less <<
NCT02578082 Renal Impairment PHASE1 COMPLETED 2025-05-16 Orlando Clinical Research Cent... More >>er (OCRC), Orlando, Florida, 32809, United States Less <<
NCT02109172 - Completed - -
NCT02581592 Hepatic Impairment PHASE1 COMPLETED 2025-04-16 Orlando Clinical Research Cent... More >>er (OCRD), Orlando, Florida, 32809, United States Less <<
NCT02109172 Chronic Obstructive Pulmonary ... More >>Disease COPD Less << Phase 2 Completed - United States, North Carolina ... More >> American Health Research Charlotte, North Carolina, United States, 28207 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.36mL

1.67mL

0.84mL

16.73mL

3.35mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories